CanSino lays groundwork for coronavirus vaccine manufacturing

May 13, 2020

China’s CanSino, which has a coronavirus vaccine in clinical trials, is planning further trials and manufacturing in Canada.

The company is reportedly working with Canada’s National Research Council (NRC) to set the stage for later-stage trials and plan scale-up for manufacturing in Montreal.

The countries have been collaborating more frequently in recent months, as Canada has sought to secure its supply chain for PPE through China. Manufacturing a vaccine in Canada could help ensure that its citizens have timely access to it. 

Canada’s regulatory arm, Health Canada, said that clinical trials in Canada will expand on data being provided from trials already underway in China. 

CanSino’s adenovirus type-5 vector-based recombinant coronavirus vaccine is one of the world’s leading candidates and advanced into phase 2 trials in April.

Read the Reuters report.